| Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia BJ Druker, F Guilhot, SG O'Brien, I Gathmann, H Kantarjian, N Gattermann, ... New England Journal of Medicine 355 (23), 2408-2417, 2006 | 4395 | 2006 |
| Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B LR Silverman, EP Demakos, BL Peterson, AB Kornblith, JC Holland, ... Journal of Clinical oncology 20 (10), 2429-2440, 2002 | 2217 | 2002 |
| A Tyrosine Kinase Created by Fusion of the PDGFRA and FIP1L1 Genes as a Therapeutic Target of Imatinib in Idiopathic Hypereosinophilic Syndrome J Cools, DJ DeAngelo, J Gotlib, EH Stover, RD Legare, J Cortes, J Kutok, ... New England Journal of Medicine 348 (13), 1201-1214, 2003 | 2153 | 2003 |
| Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation RM Stone, SJ Mandrekar, BL Sanford, K Laumann, S Geyer, ... New England Journal of Medicine 377 (5), 454-464, 2017 | 2144 | 2017 |
| Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid … JC Byrd, K Mrózek, RK Dodge, AJ Carroll, CG Edwards, DC Arthur, ... Blood, The Journal of the American Society of Hematology 100 (13), 4325-4336, 2002 | 2090 | 2002 |
| Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia BD Cheson, PL Greenberg, JM Bennett, B Lowenberg, PW Wijermans, ... Blood 108 (2), 419-425, 2006 | 1807 | 2006 |
| Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion A List, G Dewald, J Bennett, A Giagounidis, A Raza, E Feldman, B Powell, ... New England Journal of Medicine 355 (14), 1456-1465, 2006 | 1631 | 2006 |
| Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study: Presented in part at … CL Sawyers, A Hochhaus, E Feldman, JM Goldman, CB Miller, ... Blood, The Journal of the American Society of Hematology 99 (10), 3530-3539, 2002 | 1529 | 2002 |
| Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study M Talpaz, RT Silver, BJ Druker, JM Goldman, C Gambacorti-Passerini, ... Blood, The Journal of the American Society of Hematology 99 (6), 1928-1937, 2002 | 1468 | 2002 |
| Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia EM Stein, CD DiNardo, DA Pollyea, AT Fathi, GJ Roboz, JK Altman, ... Blood, The Journal of the American Society of Hematology 130 (6), 722-731, 2017 | 1461 | 2017 |
| Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML CD DiNardo, EM Stein, S de Botton, GJ Roboz, JK Altman, AS Mims, ... New England Journal of Medicine 378 (25), 2386-2398, 2018 | 1358 | 2018 |
| International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with> 30% blasts H Dombret, JF Seymour, A Butrym, A Wierzbowska, D Selleslag, JH Jang, ... Blood, The Journal of the American Society of Hematology 126 (3), 291-299, 2015 | 1302 | 2015 |
| International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data DA Arber, A Orazi, RP Hasserjian, MJ Borowitz, KR Calvo, HM Kvasnicka, ... Blood, The Journal of the American Society of Hematology 140 (11), 1200-1228, 2022 | 1122 | 2022 |
| Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials J Koreth, R Schlenk, KJ Kopecky, S Honda, J Sierra, BJ Djulbegovic, ... Jama 301 (22), 2349-2361, 2009 | 1098 | 2009 |
| United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia SL Soignet, SR Frankel, D Douer, MS Tallman, H Kantarjian, E Calleja, ... Journal of Clinical Oncology 19 (18), 3852-3860, 2001 | 1076 | 2001 |
| Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia M Konopleva, DA Pollyea, J Potluri, B Chyla, L Hogdal, T Busman, ... Cancer discovery 6 (10), 1106-1117, 2016 | 1016 | 2016 |
| Acute myeloid leukemia ontogeny is defined by distinct somatic mutations RC Lindsley, BG Mar, E Mazzola, PV Grauman, S Shareef, SL Allen, ... Blood, The Journal of the American Society of Hematology 125 (9), 1367-1376, 2015 | 969 | 2015 |
| Principios de Medicina Interna Vol. 1 TR Harrison, A Fauci, E Braunwald, K Isselbacher, J Wilson, J Martin McGraw Hill-Interamericana, 1994 | 946 | 1994 |
| Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL JA Woyach, AS Ruppert, NA Heerema, W Zhao, AM Booth, W Ding, ... New England Journal of Medicine 379 (26), 2517-2528, 2018 | 944 | 2018 |
| Report of an international working group to standardize response criteria for myelodysplastic syndromes BD Cheson, JM Bennett, H Kantarjian, A Pinto, CA Schiffer, SD Nimer, ... Blood, The Journal of the American Society of Hematology 96 (12), 3671-3674, 2000 | 916 | 2000 |
